Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation

Antonio Facciorusso, Valentina Del Prete, Matteo Antonino, Nicola Crucinio, Viviana Neve, Alfredo Di Leo, Brian I. Carr, Michele Barone

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Overall survival in hepatocellular carcinoma patients treated with percutaneous radiofrequency ablation is influenced by both recurrence and successive treatments. We investigated post-recurrence survival after radiofrequency ablation. Methods: Data on 103 early/intermediate patients initially treated with radiofrequency ablation and followed for a median of 78 months (range 68-82) were retrospectively analysed. If intrahepatic disease recurrence occurred within or contiguous to the previously treated area it was defined as local, otherwise as distant; recurrence classified as Barcelona Clinic Liver Cancer stage C was defined by neoplastic portal vein thrombosis or metastases. Results: A total of 103 patients were included (82.5% male, median age 70 years, range 39-86). During follow-up, 64 recurrences were observed. Median overall survival was 62 months (95% confidence interval: 54-78) and survival rates were 97%, 65% and 52% at 1, 4 and 5 years, respectively. Median post-recurrence survival was 22 months (95% confidence interval: 16-35). Child-Pugh score, performance status, sum of tumour diameters at recurrence and recurrence patterns were independent predictors of post-recurrence survival. Conclusions: In patients with hepatocellular carcinoma after radiofrequency ablation, clinical and tumour parameters assessed at relapse, in particular the type of recurrence pattern, influence post-recurrence survival.

Original languageEnglish
Pages (from-to)1014-1019
Number of pages6
JournalDigestive and Liver Disease
Volume46
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Hepatocellular Carcinoma
Recurrence
Survival
Confidence Intervals
Liver Neoplasms
Portal Vein
Neoplasms
Thrombosis
Survival Rate
Neoplasm Metastasis

Keywords

  • HCC
  • Liver cancer
  • PRS
  • RFA

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology
  • Medicine(all)

Cite this

Facciorusso, A., Del Prete, V., Antonino, M., Crucinio, N., Neve, V., Di Leo, A., ... Barone, M. (2014). Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Digestive and Liver Disease, 46(11), 1014-1019. https://doi.org/10.1016/j.dld.2014.07.012

Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. / Facciorusso, Antonio; Del Prete, Valentina; Antonino, Matteo; Crucinio, Nicola; Neve, Viviana; Di Leo, Alfredo; Carr, Brian I.; Barone, Michele.

In: Digestive and Liver Disease, Vol. 46, No. 11, 01.11.2014, p. 1014-1019.

Research output: Contribution to journalArticle

Facciorusso, A, Del Prete, V, Antonino, M, Crucinio, N, Neve, V, Di Leo, A, Carr, BI & Barone, M 2014, 'Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation', Digestive and Liver Disease, vol. 46, no. 11, pp. 1014-1019. https://doi.org/10.1016/j.dld.2014.07.012
Facciorusso A, Del Prete V, Antonino M, Crucinio N, Neve V, Di Leo A et al. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Digestive and Liver Disease. 2014 Nov 1;46(11):1014-1019. https://doi.org/10.1016/j.dld.2014.07.012
Facciorusso, Antonio ; Del Prete, Valentina ; Antonino, Matteo ; Crucinio, Nicola ; Neve, Viviana ; Di Leo, Alfredo ; Carr, Brian I. ; Barone, Michele. / Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. In: Digestive and Liver Disease. 2014 ; Vol. 46, No. 11. pp. 1014-1019.
@article{02bc8eb34c09411884d69ee6483c4bb9,
title = "Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation",
abstract = "Background: Overall survival in hepatocellular carcinoma patients treated with percutaneous radiofrequency ablation is influenced by both recurrence and successive treatments. We investigated post-recurrence survival after radiofrequency ablation. Methods: Data on 103 early/intermediate patients initially treated with radiofrequency ablation and followed for a median of 78 months (range 68-82) were retrospectively analysed. If intrahepatic disease recurrence occurred within or contiguous to the previously treated area it was defined as local, otherwise as distant; recurrence classified as Barcelona Clinic Liver Cancer stage C was defined by neoplastic portal vein thrombosis or metastases. Results: A total of 103 patients were included (82.5{\%} male, median age 70 years, range 39-86). During follow-up, 64 recurrences were observed. Median overall survival was 62 months (95{\%} confidence interval: 54-78) and survival rates were 97{\%}, 65{\%} and 52{\%} at 1, 4 and 5 years, respectively. Median post-recurrence survival was 22 months (95{\%} confidence interval: 16-35). Child-Pugh score, performance status, sum of tumour diameters at recurrence and recurrence patterns were independent predictors of post-recurrence survival. Conclusions: In patients with hepatocellular carcinoma after radiofrequency ablation, clinical and tumour parameters assessed at relapse, in particular the type of recurrence pattern, influence post-recurrence survival.",
keywords = "HCC, Liver cancer, PRS, RFA",
author = "Antonio Facciorusso and {Del Prete}, Valentina and Matteo Antonino and Nicola Crucinio and Viviana Neve and {Di Leo}, Alfredo and Carr, {Brian I.} and Michele Barone",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.dld.2014.07.012",
language = "English",
volume = "46",
pages = "1014--1019",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "11",

}

TY - JOUR

T1 - Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation

AU - Facciorusso, Antonio

AU - Del Prete, Valentina

AU - Antonino, Matteo

AU - Crucinio, Nicola

AU - Neve, Viviana

AU - Di Leo, Alfredo

AU - Carr, Brian I.

AU - Barone, Michele

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background: Overall survival in hepatocellular carcinoma patients treated with percutaneous radiofrequency ablation is influenced by both recurrence and successive treatments. We investigated post-recurrence survival after radiofrequency ablation. Methods: Data on 103 early/intermediate patients initially treated with radiofrequency ablation and followed for a median of 78 months (range 68-82) were retrospectively analysed. If intrahepatic disease recurrence occurred within or contiguous to the previously treated area it was defined as local, otherwise as distant; recurrence classified as Barcelona Clinic Liver Cancer stage C was defined by neoplastic portal vein thrombosis or metastases. Results: A total of 103 patients were included (82.5% male, median age 70 years, range 39-86). During follow-up, 64 recurrences were observed. Median overall survival was 62 months (95% confidence interval: 54-78) and survival rates were 97%, 65% and 52% at 1, 4 and 5 years, respectively. Median post-recurrence survival was 22 months (95% confidence interval: 16-35). Child-Pugh score, performance status, sum of tumour diameters at recurrence and recurrence patterns were independent predictors of post-recurrence survival. Conclusions: In patients with hepatocellular carcinoma after radiofrequency ablation, clinical and tumour parameters assessed at relapse, in particular the type of recurrence pattern, influence post-recurrence survival.

AB - Background: Overall survival in hepatocellular carcinoma patients treated with percutaneous radiofrequency ablation is influenced by both recurrence and successive treatments. We investigated post-recurrence survival after radiofrequency ablation. Methods: Data on 103 early/intermediate patients initially treated with radiofrequency ablation and followed for a median of 78 months (range 68-82) were retrospectively analysed. If intrahepatic disease recurrence occurred within or contiguous to the previously treated area it was defined as local, otherwise as distant; recurrence classified as Barcelona Clinic Liver Cancer stage C was defined by neoplastic portal vein thrombosis or metastases. Results: A total of 103 patients were included (82.5% male, median age 70 years, range 39-86). During follow-up, 64 recurrences were observed. Median overall survival was 62 months (95% confidence interval: 54-78) and survival rates were 97%, 65% and 52% at 1, 4 and 5 years, respectively. Median post-recurrence survival was 22 months (95% confidence interval: 16-35). Child-Pugh score, performance status, sum of tumour diameters at recurrence and recurrence patterns were independent predictors of post-recurrence survival. Conclusions: In patients with hepatocellular carcinoma after radiofrequency ablation, clinical and tumour parameters assessed at relapse, in particular the type of recurrence pattern, influence post-recurrence survival.

KW - HCC

KW - Liver cancer

KW - PRS

KW - RFA

UR - http://www.scopus.com/inward/record.url?scp=84908241374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908241374&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2014.07.012

DO - 10.1016/j.dld.2014.07.012

M3 - Article

C2 - 25085684

AN - SCOPUS:84908241374

VL - 46

SP - 1014

EP - 1019

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 11

ER -